Our vision is to develop novel medicines for cough
Attenua is a clinical-stage biotechnology company developing novel medicines for cough.
Attenua’s lead drug candidate, bradanicline, which targets a new mechanism for cough, is expected to enter Phase 2 clinical development for chronic cough in late 2018.
Cough is a medical problem for which no new drugs (NMEs/NCEs) have been approved in the U.S. since 1958. The prevalence of chronic cough — defined as lasting more than eight weeks — is estimated to be more than 10% of adults in the United States. While underlying etiologies may contribute to cough in some of these patients (such as asthma, gastroesophageal reflux disease, and upper airway cough syndrome), many patients are not well-controlled for their cough even with treatment for these underlying causes. No therapies are approved for the treatment of chronic cough.
The company raised $35 million in a Series A financing from leading life sciences investors in April 2018.